PRECISION BIOSCIENCES INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precision BioSciences reported Q2 2026 results with clinical milestone data from PBGENE-HBV showing first-ever biopsy proof of direct cccDNA elimination (1-log reduction in one patient, <1% remaining after 2 doses at 0.4 mg/kg) and sustained pgRNA loss in 100% of evaluable patients. The company has $112.4M in cash as of June 30, 2026, expected to fund operations through 2028. Q2 net loss was $32.7M ($1.26/share); G&A costs decreased $2.3M YoY but warrant liability fair-value adjustments increased $13.5M non-cash loss YoY.
Why this rating
Significant clinical validation of core HBV program de-risks key technology question and supports potential regulatory pathway; cash runway adequate through 2028 removes near-term dilution risk. Event is ~150% of current market cap in meaningful value, but execution and regulatory approval remain unproven.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.